Last reviewed 2026-06-10 · How we verify

Cystic Fibrosis with Burkholderia spp. Infection — Treatment Landscape & Competitive Intelligence

Cystic Fibrosis with Burkholderia spp. Infection (disease) competitive landscape: 0 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Cystic Fibrosis with Burkholderia spp. Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

No marketed treatments tracked for this disease yet.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. AlgiPharma AS · 1 drug in Cystic Fibrosis with Burkholderia spp. Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Cystic Fibrosis with Burkholderia spp. Infection:

• Cystic Fibrosis with Burkholderia spp. Infection treatment updates — RSS
• Cystic Fibrosis with Burkholderia spp. Infection treatment updates — Atom
• Cystic Fibrosis with Burkholderia spp. Infection treatment updates — JSON

Cite this brief

Drug Landscape (2026). Cystic Fibrosis with Burkholderia spp. Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/cystic-fibrosis-with-burkholderia-spp-infection. Accessed 2026-06-10.

Related

• Cystic Fibrosis with Burkholderia spp. Infection full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing